Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

CONCLUSIONS: These findings demonstrate the on-target effect of venetoclax and offer potential mechanisms to overcome acquired and intrinsic venetoclax resistance through PI3K/AKT inhibition.
PMID: 29666304 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 17, 2018 Category: Cancer & Oncology Authors: Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin JR, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M Tags: Clin Cancer Res Source Type: research